Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $9.2 million.

  • SAB Biotherapeutics' Shares Outstanding (Weighted Average) rose 12.80% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 12.80%. This contributed to the annual value of $9.2 million for FY2024, which is 76.40% up from last year.
  • SAB Biotherapeutics' Shares Outstanding (Weighted Average) amounted to $9.2 million in FY2024, which was up 76.40% from $5.2 million recorded in FY2023.
  • SAB Biotherapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $9.2 million during FY2024, with a 5-year trough of $4.3 million in FY2022.
  • Over the past 3 years, SAB Biotherapeutics' median Shares Outstanding (Weighted Average) value was $5.2 million (recorded in 2023), while the average stood at $6.3 million.
  • In the last 5 years, SAB Biotherapeutics' Shares Outstanding (Weighted Average) fell by 1.02% in 2022 and then spiked by 76.40% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $4.4 million in 2020, then fell by 0.96% to $4.3 million in 2021, then fell by 1.02% to $4.3 million in 2022, then grew by 21.59% to $5.2 million in 2023, then skyrocketed by 76.40% to $9.2 million in 2024.